<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-131366" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cannabis Use for Glaucoma and Associated Pain</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lopez</surname>
            <given-names>Maria J.</given-names>
          </name>
          <aff>BronxCare Health System</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nataneli</surname>
            <given-names>Nathaniel</given-names>
          </name>
          <aff>BronxCare Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maria Lopez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nathaniel Nataneli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-131366.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Cannabis plants and their derivatives delta(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD) have been evaluated for the treatment of many disorders, including lowering intraocular pressure (IOP). Control of IOP is the most significant modifiable risk factor for glaucoma, an optic neuropathy that causes irreversible blindness. This activity reviews cannabinoids&#x02019; mechanisms of action in lowering intraocular pressure, their potential neuroprotective properties, and local and systemic side effects.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the mechanisms by which cannabinoids decrease intraocular pressure.</p></list-item><list-item><p>Describe the proposed pathways through which cannabinoids may exert their neuroprotective effect.</p></list-item><list-item><p>Identify the most common systemic side effects associated with cannabis use.</p></list-item><list-item><p>Review the most common acute psychotropic side effects associated with cannabis use.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=131366&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=131366">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-131366.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Glaucoma is an optic neuropathy characterized by the loss of retinal ganglion cells and subsequent progressive degeneration of the optic nerve. It is the most common cause of irreversible blindness in the world. The most significant modifiable risk factor is the control of intraocular pressure (IOP).<xref ref-type="bibr" rid="article-131366.r1">[1]</xref></p>
        <p><italic toggle="yes">Cannabis </italic>plants have been used as a therapeutic agent for many centuries, as early as the fourth century AD.<xref ref-type="bibr" rid="article-131366.r2">[2]</xref>&#x000a0;More recently, cannabis&#x02019; primary psychoactive component delta(9)-tetrahydrocannabinol (THC) and its major non-psychoactive ingredient cannabidiol (CBD) have been used for the treatment of sleep disorders, pain, skin disorders,&#x000a0;and lowering of intraocular pressure (IOP).<xref ref-type="bibr" rid="article-131366.r3">[3]</xref><xref ref-type="bibr" rid="article-131366.r4">[4]</xref><xref ref-type="bibr" rid="article-131366.r5">[5]</xref><xref ref-type="bibr" rid="article-131366.r6">[6]</xref><xref ref-type="bibr" rid="article-131366.r7">[7]</xref><xref ref-type="bibr" rid="article-131366.r8">[8]</xref><xref ref-type="bibr" rid="article-131366.r9">[9]</xref>&#x000a0;</p>
        <p>Cannabinoid (CB) receptors are G protein receptors with an affinity for the agonists THC and CBD. Two types of CB receptors are described: CB1 and CB2. CB1 receptors are mostly limited to the central nervous system, where they modulate neurotransmitters, while CB2 receptors are confined to the immune and peripheral nervous system and are involved in cytokine signaling.<xref ref-type="bibr" rid="article-131366.r10">[10]</xref></p>
      </sec>
      <sec id="article-131366.s3" sec-type="Function">
        <title>Function</title>
        <p>
<bold>Cannabinoid Receptors in the Eye</bold>
</p>
        <p>CB1 and CB2 receptors have been identified widely in the eye. CB1 receptors have been identified in corneal epithelium and endothelium, ciliary body, iris, Schlemm canal, trabecular meshwork, choroid, and many retinal layers: ganglion cell, inner and outer plexiform, inner nuclear, and outer segments of photoreceptors cells.<xref ref-type="bibr" rid="article-131366.r11">[11]</xref>&#x000a0;CB2 receptors have been found in the corneal epithelium&#x000a0;and, like CB1 receptors, in many retinal layers: ganglion cell nuclear layer, inner nuclear, and inner segments of photoreceptors cells.<xref ref-type="bibr" rid="article-131366.r12">[12]</xref><xref ref-type="bibr" rid="article-131366.r13">[13]</xref></p>
        <p>
<bold>Cannabinoids Effects on Intraocular Pressure</bold>
</p>
        <p>THC has been identified as the metabolite relevant to IOP-lowering, and this potential to treat glaucoma has been the subject of research over the past five decades.<xref ref-type="bibr" rid="article-131366.r8">[8]</xref><xref ref-type="bibr" rid="article-131366.r9">[9]</xref></p>
        <p>Reports about the use of THC to regulate IOP date back to 1971 when Helper and Frank published preliminary data about the effect of marijuana in lowering IOP, in which healthy patients demonstrated a 25% decrease in IOP after smoking THC.<xref ref-type="bibr" rid="article-131366.r14">[14]</xref>. A subsequent study demonstrated a 30% decrease in IOP in glaucoma patients, although this effect lasted only 4 to 5 hours.<xref ref-type="bibr" rid="article-131366.r15">[15]</xref>&#x000a0;The first placebo-controlled study also demonstrated a significant but transient (four hours) decrease in IOP after inhalation of THC.<xref ref-type="bibr" rid="article-131366.r16">[16]</xref></p>
        <p>Other delivery methods have been studied in human and animal models with variable results. Healthy human subjects received intravenous (IV) THC at different doses resulting in a moderate decrease in IOP (average 37% decrease) with a reported increase in heart rate and pulse.<xref ref-type="bibr" rid="article-131366.r17">[17]</xref>&#x000a0;Tiedeman et al. tested two oral derivatives of THC in a double-masked study in patients with ocular hypertension. Only one of the compounds effectively decreased IOP independently of blood pressure with mild subjective side effects.<xref ref-type="bibr" rid="article-131366.r18">[18]</xref>&#x000a0;In a cross-over study conducted by Tomida et al., sublingual THC administration at a low dose (5 mg) effectively decreased IOP after two hours, with IOP returning to baseline levels after four hours. In the same study, patients who received CBD did not show changes in IOP at any time, and patients who received a higher dose of THC (40 mg) had a transient increase in IOP.<xref ref-type="bibr" rid="article-131366.r19">[19]</xref></p>
        <p>One of the challenges of topical administration of THC is its poor aqueous solubility. In a study conducted in rabbits, combining a TCH prodrug with surfactants and cyclodextrins helped improve aqueous solubility and corneal permeability compared to THC alone. Its IOP lowering capacity was comparable in duration and potency to timolol and pilocarpine.<xref ref-type="bibr" rid="article-131366.r20">[20]</xref>&#x000a0;In another human study, the use of a CB1 receptor agonist combined with cyclodextrin demonstrated a peak reduction of IOP after one hour of administration; this effect subsided within two hours.<xref ref-type="bibr" rid="article-131366.r21">[21]</xref>&#x000a0;Green et al. demonstrated that although topical administration of THC alone was not associated with any signs of ocular toxicity, it did not result in any significant decrease in IOP either.<xref ref-type="bibr" rid="article-131366.r22">[22]</xref></p>
        <p>The exact mechanism by which cannabinoids decrease IOP has not been elucidated. It has been proposed that CB1 receptors in the trabecular meshwork, Schelmm canal, and ciliary body may modulate aqueous production and also improve trabecular outflow.<xref ref-type="bibr" rid="article-131366.r23">[23]</xref><xref ref-type="bibr" rid="article-131366.r24">[24]</xref>&#x000a0;Also, the lowering IOP effect might be related to a decrease in systemic blood pressure with concurrently decreased pressure perfusing the ciliary body.<xref ref-type="bibr" rid="article-131366.r16">[16]</xref>&#x000a0;Cannabinoids&#x02019; vasodilatory effects may also play a role in promoting uveoscleral outflow with subsequent lowering of IOP.<xref ref-type="bibr" rid="article-131366.r24">[24]</xref></p>
        <p>
<bold>Cannabinoids: Neuroprotective Effects</bold>
</p>
        <p>It has been hypothesized that THC may play a role in neuroprotection. In one study, healthy human subjects were administered a low dose of dronabinol, a synthetic form of THC, and an improvement in optic nerve head blood flow at rest was noted. However, IOP, ocular perfusion pressure (OPP), and mean arterial pressure (MAP) did not show any changes. Also, low-dose oral administration did not induce any psychoactive side effects.<xref ref-type="bibr" rid="article-131366.r25">[25]</xref></p>
        <p>In another study in healthy human subjects, oral administration of a slightly higher dose of dronabinol resulted in a significant decrease in IOP and improved retinal arteriovenous passage time, indicating an increase in retinal hemodynamics suggesting potential use in ocular disorders associated with inadequate blood perfusion. This study showed no adverse cardiovascular or respiratory side effects.<xref ref-type="bibr" rid="article-131366.r26">[26]</xref></p>
        <p>Other animal studies have shown that systemic administration of cannabinoids may increase blood flow to the choroid, iris, and ciliary body&#x000a0;and reduce retinal ganglion cell layer loss in animal models of ischemic/traumatic optic nerve injury.<xref ref-type="bibr" rid="article-131366.r27">[27]</xref><xref ref-type="bibr" rid="article-131366.r28">[28]</xref><xref ref-type="bibr" rid="article-131366.r29">[29]</xref>&#x000a0;In one animal model of ischemia-reperfusion, IOP was artificially elevated, and animal groups were treated with either CB1 receptor agonists alone or combined with CB1 antagonist at different concentrations, followed by quantification of any ischemic damage to retinal ganglion cells (RGC). RGC density was noticeably higher in the group treated with CB1 agonist alone. Co-treatment with antagonists almost completely abolished the neuroprotective effect.<xref ref-type="bibr" rid="article-131366.r30">[30]</xref></p>
        <p>There are three proposed pathways through which cannabinoids exert their neuroprotective effect: inhibition of glutamate, nitric oxide, and endothelin-1. It is known that glutamate is toxic to RGC in glaucoma and has been implicated in progressive degeneration in chronic optic neuropathies.<xref ref-type="bibr" rid="article-131366.r31">[31]</xref>&#x000a0;Glutamate activates nitric oxide synthase with a subsequent increase in oxidative damage.<xref ref-type="bibr" rid="article-131366.r32">[32]</xref>&#x000a0;Activation of CB1 and CB2 receptors leads to inhibition of glutamate release, suggesting that activating these receptors could be a way to protect RGCs from glutamate-induced death.<xref ref-type="bibr" rid="article-131366.r33">[33]</xref>&#x000a0;At the same time, such activation in the retina and central nervous system inhibits nitric oxide production and inflammatory cytokines that contribute to oxidative stress and loss of RGCs.<xref ref-type="bibr" rid="article-131366.r34">[34]</xref>&#x000a0;</p>
        <p>Cannabinoids also have vasodilation properties; once CB1 and CB2 receptors are activated, there is an inhibition of endothelin-1 release. Inhibition of endothelin-1 vasoconstrictive effect results in increased blood supply to the optic nerve head, which can play a neuroprotective role in disease progression.<xref ref-type="bibr" rid="article-131366.r35">[35]</xref></p>
      </sec>
      <sec id="article-131366.s4" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>
<bold>Cannabinoids: Deleterious Effects in the Retina</bold>
</p>
        <p>Some published data suggest that cannabinoids may be deleterious to retinal and ganglion cells. Lucas et al. studied the relationship between cannabis use and retinal neural activity in a resting state in the absence of stimulation, a phenomenon known as background noise. Their findings suggest that THC use is associated with increased neuronal background noise in the retina and the brain. This may reflect the neurotoxicity of cannabis on retinal neuron dynamic, likely attributable to altered neurotransmitter release.<xref ref-type="bibr" rid="article-131366.r36">[36]</xref>&#x000a0;</p>
        <p>Schwitzer et al. have shown a delay in responses of ganglion and bipolar cells in regular cannabis users that translate into delay of visual information transmission from the retina to the brain. Utilizing multifocal electroretinogram, they demonstrated that this delay in transmission could translate into alterations in precise and color vision. This same author also published a report of transient dysfunction of retinal activity thirty minutes after cannabis use by smoking. There was a marked decrease in the amplitude of the a-wave in electroretinogram compared with the responses five hours after smoking.<xref ref-type="bibr" rid="article-131366.r37">[37]</xref><xref ref-type="bibr" rid="article-131366.r38">[38]</xref><xref ref-type="bibr" rid="article-131366.r39">[39]</xref>&#x000a0;These data have opened the field for further investigations about the impact of cannabis on retinal processing.</p>
        <p><bold>Cannabinoids: Systemic Side Effects</bold>&#x000a0;</p>
        <p>Cannabis use is associated with behavioral and end-organ toxicity&#x000a0;and is contraindicated in the context of significant hepatic, renal, cardiovascular, or psychiatric disease.<xref ref-type="bibr" rid="article-131366.r40">[40]</xref><xref ref-type="bibr" rid="article-131366.r41">[41]</xref><xref ref-type="bibr" rid="article-131366.r42">[42]</xref>&#x000a0;Its use produces impairment in social and cognitive functions and may be associated with the use of other illicit drugs.<xref ref-type="bibr" rid="article-131366.r43">[43]</xref>&#x000a0;Acute effects are euphoria, relaxation, time distortion, perceptual alteration, and intensification of normal sensory experiences. Acute cannabis intoxication can cause impairment of short-term memory, attention, reaction time, and motor skills. Some users can develop anxiety and panic reactions.<xref ref-type="bibr" rid="article-131366.r44">[44]</xref>&#x000a0;It can also cause tachycardia within minutes of use and hypotension. Other systemic effects associated with chronic use of cannabis are impaired cell-mediated and humoral immunity, chronic bronchitis, increased risk of lung cancer, and male and female infertility.<xref ref-type="bibr" rid="article-131366.r45">[45]</xref><xref ref-type="bibr" rid="article-131366.r44">[44]</xref></p>
      </sec>
      <sec id="article-131366.s5" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Further studies may help elucidate any IOP-independent potential neuroprotective benefits. In a 2009 statement, the American Glaucoma Society recommended against marijuana use in any form for the treatment of glaucoma.<xref ref-type="bibr" rid="article-131366.r46">[46]</xref></p>
      </sec>
      <sec id="article-131366.s6" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing patients who may independently choose to use cannabinoids to treat glaucoma&#x000a0;requires an interprofessional team of healthcare professionals that may include a nurse, pharmacist, and several physicians in different specialties to improve outcomes and reduce morbidity.&#x000a0;A patient may report their use of cannabinoids to the ophthalmic nurse or technician, and the ophthalmologist must educate the patient about&#x000a0;the lack of clear evidence demonstrating these agents' usefulness in the treatment of glaucoma as the importance to not stop using proven glaucoma therapies.<xref ref-type="bibr" rid="article-131366.r47">[47]</xref>&#x000a0;[Level 1]</p>
        <p>The care of such a patient does not stop at this discussion. Because of cannabinoids'&#x000a0;potentially addictive nature, secondary systemic and psychotropic side effects, very short duration of action, management of chronic cannabinoid use in a patient, especially in the presence of comorbidities or mobility impairments, will also require the collaboration of the patient's primary care doctor, behavior and mental health professionals, and home health aides.<xref ref-type="bibr" rid="article-131366.r40">[40]</xref><xref ref-type="bibr" rid="article-131366.r41">[41]</xref><xref ref-type="bibr" rid="article-131366.r40">[40]</xref>&#x000a0;[Level&#x000a0;5, 3]</p>
      </sec>
      <sec id="article-131366.s7">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=131366&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=131366">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/131366/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=131366">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-131366.s8">
        <title>References</title>
        <ref id="article-131366.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jonas</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Aung</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bourne</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Bron</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ritch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Panda-Jonas</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Glaucoma.</article-title>
            <source>Lancet</source>
            <year>2017</year>
            <month>Nov</month>
            <day>11</day>
            <volume>390</volume>
            <issue>10108</issue>
            <fpage>2183</fpage>
            <page-range>2183-2193</page-range>
            <pub-id pub-id-type="pmid">28577860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zias</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stark</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sellgman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Werker</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Breuer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mechoulam</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Early medical use of cannabis.</article-title>
            <source>Nature</source>
            <year>1993</year>
            <month>May</month>
            <day>20</day>
            <volume>363</volume>
            <issue>6426</issue>
            <fpage>215</fpage>
            <pub-id pub-id-type="pmid">8387642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murillo-Rodr&#x000ed;guez</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The role of the CB1 receptor in the regulation of sleep.</article-title>
            <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
            <year>2008</year>
            <month>Aug</month>
            <day>01</day>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>1420</fpage>
            <page-range>1420-7</page-range>
            <pub-id pub-id-type="pmid">18514375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Burnell-Nugent</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lossignol</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ganae-Motan</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Potts</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fallon</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.</article-title>
            <source>J Pain Symptom Manage</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-79</page-range>
            <pub-id pub-id-type="pmid">19896326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rog</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Nurmikko</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.</article-title>
            <source>Clin Ther</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>9</issue>
            <fpage>2068</fpage>
            <page-range>2068-79</page-range>
            <pub-id pub-id-type="pmid">18035205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rog</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Nurmikko</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Friede</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.</article-title>
            <source>Neurology</source>
            <year>2005</year>
            <month>Sep</month>
            <day>27</day>
            <volume>65</volume>
            <issue>6</issue>
            <fpage>812</fpage>
            <page-range>812-9</page-range>
            <pub-id pub-id-type="pmid">16186518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mounessa</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dunnick</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Dellavalle</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>The role of cannabinoids in dermatology.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>77</volume>
            <issue>1</issue>
            <fpage>188</fpage>
            <page-range>188-190</page-range>
            <pub-id pub-id-type="pmid">28416341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Daily</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leishman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bradshaw</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Straiker</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>&#x00394;9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2018</year>
            <month>Dec</month>
            <day>03</day>
            <volume>59</volume>
            <issue>15</issue>
            <fpage>5904</fpage>
            <page-range>5904-5911</page-range>
            <pub-id pub-id-type="pmid">30550613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merritt</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>BF</given-names>
              </name>
            </person-group>
            <article-title>Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1981</year>
            <season>Aug-Sep</season>
            <volume>21</volume>
            <issue>S1</issue>
            <fpage>467S</fpage>
            <page-range>467S-471S</page-range>
            <pub-id pub-id-type="pmid">6271841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amin</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology of Medical Cannabis.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2019</year>
            <volume>1162</volume>
            <fpage>151</fpage>
            <page-range>151-165</page-range>
            <pub-id pub-id-type="pmid">31332738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porcella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maxia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gessa</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Pani</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein.</article-title>
            <source>Eur J Neurosci</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>1123</fpage>
            <page-range>1123-7</page-range>
            <pub-id pub-id-type="pmid">10762343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murataeva</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dhopeshwarkar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leishman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Daily</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Morton</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lashmet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bradshaw</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hillard</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Straiker</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cannabinoid CB2R receptors are upregulated with corneal injury and regulate the course of corneal wound healing.</article-title>
            <source>Exp Eye Res</source>
            <year>2019</year>
            <month>May</month>
            <volume>182</volume>
            <fpage>74</fpage>
            <page-range>74-84</page-range>
            <pub-id pub-id-type="pmid">30905716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Straiker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Maguire</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Expression of CB2 cannabinoid receptor mRNA in adult rat retina.</article-title>
            <source>Vis Neurosci</source>
            <year>2000</year>
            <season>Jan-Feb</season>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>91</fpage>
            <page-range>91-5</page-range>
            <pub-id pub-id-type="pmid">10750830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hepler</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Frank</surname>
                <given-names>IR</given-names>
              </name>
            </person-group>
            <article-title>Marihuana smoking and intraocular pressure.</article-title>
            <source>JAMA</source>
            <year>1971</year>
            <month>Sep</month>
            <day>06</day>
            <volume>217</volume>
            <issue>10</issue>
            <fpage>1392</fpage>
            <pub-id pub-id-type="pmid">5109652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The 94-day cannabis study.</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>1976</year>
            <volume>282</volume>
            <fpage>211</fpage>
            <page-range>211-20</page-range>
            <pub-id pub-id-type="pmid">1071381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merritt</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Anduze</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Gelbart</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Effect of marihuana on intraocular and blood pressure in glaucoma.</article-title>
            <source>Ophthalmology</source>
            <year>1980</year>
            <month>Mar</month>
            <volume>87</volume>
            <issue>3</issue>
            <fpage>222</fpage>
            <page-range>222-8</page-range>
            <pub-id pub-id-type="pmid">7053160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gregg</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Effect of delta-9-tetrahydrocannabinol on intraocular pressure in humans.</article-title>
            <source>South Med J</source>
            <year>1977</year>
            <month>Aug</month>
            <volume>70</volume>
            <issue>8</issue>
            <fpage>951</fpage>
            <page-range>951-4</page-range>
            <pub-id pub-id-type="pmid">329423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tiedeman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Crow</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Cocchetto</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Howes</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Effect of synthetic cannabinoids on elevated intraocular pressure.</article-title>
            <source>Ophthalmology</source>
            <year>1981</year>
            <month>Mar</month>
            <volume>88</volume>
            <issue>3</issue>
            <fpage>270</fpage>
            <page-range>270-7</page-range>
            <pub-id pub-id-type="pmid">7015221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomida</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Azuara-Blanco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>House</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Flint</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pertwee</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Robson</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study.</article-title>
            <source>J Glaucoma</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>349</fpage>
            <page-range>349-53</page-range>
            <pub-id pub-id-type="pmid">16988594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adelli</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Bhagav</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Taskar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hingorani</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pettaway</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gul</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>ElSohly</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Repka</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Majumdar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Development of a &#x00394;9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2017</year>
            <month>Apr</month>
            <day>01</day>
            <volume>58</volume>
            <issue>4</issue>
            <fpage>2167</fpage>
            <page-range>2167-2179</page-range>
            <pub-id pub-id-type="pmid">28399267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porcella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maxia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gessa</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Pani</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies.</article-title>
            <source>Eur J Neurosci</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>409</fpage>
            <page-range>409-12</page-range>
            <pub-id pub-id-type="pmid">11168547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Ocular effects of topical administration of delta 9-tetrahydrocannabinol in man.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1982</year>
            <month>Feb</month>
            <volume>100</volume>
            <issue>2</issue>
            <fpage>265</fpage>
            <page-range>265-7</page-range>
            <pub-id pub-id-type="pmid">6279061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chien</surname>
                <given-names>FY</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Mittag</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Podos</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>121</volume>
            <issue>1</issue>
            <fpage>87</fpage>
            <page-range>87-90</page-range>
            <pub-id pub-id-type="pmid">12523891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porcella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Casellas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gessa</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Pani</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana.</article-title>
            <source>Brain Res Mol Brain Res</source>
            <year>1998</year>
            <month>Jul</month>
            <day>15</day>
            <volume>58</volume>
            <issue>1-2</issue>
            <fpage>240</fpage>
            <page-range>240-5</page-range>
            <pub-id pub-id-type="pmid">9685662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hommer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kallab</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Szegedi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Puchner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stjepanek</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Werkmeister</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Schmetterer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Abensperg-Traun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garh&#x000f6;fer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schmidl</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>108</volume>
            <issue>1</issue>
            <fpage>155</fpage>
            <page-range>155-161</page-range>
            <pub-id pub-id-type="pmid">31977076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plange</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Arend</surname>
                <given-names>KO</given-names>
              </name>
              <name>
                <surname>Kaup</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Doehmen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hendricks</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cordes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Huth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sponsel</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Remky</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Dronabinol and retinal hemodynamics in humans.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>143</volume>
            <issue>1</issue>
            <fpage>173</fpage>
            <page-range>173-4</page-range>
            <pub-id pub-id-type="pmid">17188063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wynn</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Padgett</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Effects of delta9-tetrahydrocannabinol on ocular blood flow and aqueous humor formation.</article-title>
            <source>Exp Eye Res</source>
            <year>1978</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-9</page-range>
            <pub-id pub-id-type="pmid">624325</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crandall</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Matragoon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khalifa</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Borlongan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Caldwell</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Liou</surname>
                <given-names>GI</given-names>
              </name>
            </person-group>
            <article-title>Neuroprotective and intraocular pressure-lowering effects of (-)Delta9-tetrahydrocannabinol in a rat model of glaucoma.</article-title>
            <source>Ophthalmic Res</source>
            <year>2007</year>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>69</fpage>
            <page-range>69-75</page-range>
            <pub-id pub-id-type="pmid">17284931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nucci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gasperi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tartaglione</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cerulli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Terrinoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Simone</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Agr&#x000f2;</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Morrone</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Corasaniti</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Bagetta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maccarrone</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Involvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>48</volume>
            <issue>7</issue>
            <fpage>2997</fpage>
            <page-range>2997-3004</page-range>
            <pub-id pub-id-type="pmid">17591864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinar-Sueiro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zorrilla Hurtado</surname>
                <given-names>J&#x000c1;</given-names>
              </name>
              <name>
                <surname>Veiga-Crespo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Vecino</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Neuroprotective effects of topical CB1 agonist WIN 55212-2 on retinal ganglion cells after acute rise in intraocular pressure induced ischemia in rat.</article-title>
            <source>Exp Eye Res</source>
            <year>2013</year>
            <month>May</month>
            <volume>110</volume>
            <fpage>55</fpage>
            <page-range>55-8</page-range>
            <pub-id pub-id-type="pmid">23454099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sucher</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Dreyer</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>Molecular basis of glutamate toxicity in retinal ganglion cells.</article-title>
            <source>Vision Res</source>
            <year>1997</year>
            <month>Dec</month>
            <volume>37</volume>
            <issue>24</issue>
            <fpage>3483</fpage>
            <page-range>3483-93</page-range>
            <pub-id pub-id-type="pmid">9425525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vorwerk</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Zurakowski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hyman</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Sabel</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Dreyer</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>37</volume>
            <issue>8</issue>
            <fpage>1618</fpage>
            <page-range>1618-24</page-range>
            <pub-id pub-id-type="pmid">8675405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Remessy</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Khalil</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Matragoon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abou-Mohamed</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Roon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Caldwell</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Caldwell</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Liou</surname>
                <given-names>GI</given-names>
              </name>
            </person-group>
            <article-title>Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite.</article-title>
            <source>Am J Pathol</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>163</volume>
            <issue>5</issue>
            <fpage>1997</fpage>
            <page-range>1997-2008</page-range>
            <pub-id pub-id-type="pmid">14578199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krishnan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Endocannabinoids alleviate proinflammatory conditions by modulating innate immune response in muller glia during inflammation.</article-title>
            <source>Glia</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>60</volume>
            <issue>11</issue>
            <fpage>1629</fpage>
            <page-range>1629-45</page-range>
            <pub-id pub-id-type="pmid">22807196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Investigations on the association between normal tension glaucoma and single nucleotide polymorphisms of the endothelin-1 and endothelin receptor genes.</article-title>
            <source>Mol Vis</source>
            <year>2006</year>
            <month>Aug</month>
            <day>29</day>
            <volume>12</volume>
            <fpage>1016</fpage>
            <page-range>1016-21</page-range>
            <pub-id pub-id-type="pmid">16971893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lucas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thirion</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schwan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Krieg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Angioi-Duprez</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Laprevote</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Schwitzer</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Association between increased retinal background noise and co-occurrent regular cannabis and alcohol use.</article-title>
            <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
            <year>2019</year>
            <month>Mar</month>
            <day>08</day>
            <volume>89</volume>
            <fpage>335</fpage>
            <page-range>335-340</page-range>
            <pub-id pub-id-type="pmid">30292729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwitzer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Henrion</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Sarre</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Albuisson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Angioi-Duprez</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Giersch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lalanne</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schwan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Laprevote</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Spatial localization of retinal anomalies in regular cannabis users: The relevance of the multifocal electroretinogram.</article-title>
            <source>Schizophr Res</source>
            <year>2020</year>
            <month>May</month>
            <volume>219</volume>
            <fpage>56</fpage>
            <page-range>56-61</page-range>
            <pub-id pub-id-type="pmid">30696610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwitzer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schwan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Albuisson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Giersch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lalanne</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Angioi-Duprez</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Laprevote</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Association Between Regular Cannabis Use and Ganglion Cell Dysfunction.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2017</year>
            <month>Jan</month>
            <day>01</day>
            <volume>135</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-60</page-range>
            <pub-id pub-id-type="pmid">27930757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwitzer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Giersch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Angioi-Duprez</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ingster-Moati</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pon-Monnier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schwan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Laprevote</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Transient Retinal Dysfunctions after Acute Cannabis Use.</article-title>
            <source>Eur Addict Res</source>
            <year>2016</year>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>287</fpage>
            <page-range>287-291</page-range>
            <pub-id pub-id-type="pmid">27376753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kazory</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aiyer</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Synthetic marijuana and acute kidney injury: an unforeseen association.</article-title>
            <source>Clin Kidney J</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>330</fpage>
            <page-range>330-3</page-range>
            <pub-id pub-id-type="pmid">26064495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zawatsky</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Abdalla</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cinar</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Synthetic cannabinoids induce acute lung inflammation <italic>via</italic> cannabinoid receptor 1 activation.</article-title>
            <source>ERJ Open Res</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>6</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">32832534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lucas</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Galettis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The pharmacokinetics and the pharmacodynamics of cannabinoids.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>84</volume>
            <issue>11</issue>
            <fpage>2477</fpage>
            <page-range>2477-2482</page-range>
            <pub-id pub-id-type="pmid">30001569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fergusson</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Horwood</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Early onset cannabis use and psychosocial adjustment in young adults.</article-title>
            <source>Addiction</source>
            <year>1997</year>
            <month>Mar</month>
            <volume>92</volume>
            <issue>3</issue>
            <fpage>279</fpage>
            <page-range>279-96</page-range>
            <pub-id pub-id-type="pmid">9219390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Pertwee</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological actions and therapeutic uses of cannabis and cannabinoids.</article-title>
            <source>Anaesthesia</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>56</volume>
            <issue>11</issue>
            <fpage>1059</fpage>
            <page-range>1059-68</page-range>
            <pub-id pub-id-type="pmid">11703238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sridhar</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Raub</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Weatherby</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Metsch</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Surratt</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Inciardi</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Duncan</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Anwyl</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>McCoy</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Possible role of marijuana smoking as a carcinogen in the development of lung cancer at a young age.</article-title>
            <source>J Psychoactive Drugs</source>
            <year>1994</year>
            <season>Jul-Sep</season>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>285</fpage>
            <page-range>285-8</page-range>
            <pub-id pub-id-type="pmid">7844658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jampel</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>American glaucoma society position statement: marijuana and the treatment of glaucoma.</article-title>
            <source>J Glaucoma</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>75</fpage>
            <page-range>75-6</page-range>
            <pub-id pub-id-type="pmid">20160576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131366.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heijl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leske</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Bengtsson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hyman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bengtsson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hussein</surname>
                <given-names>M</given-names>
              </name>
              <collab>Early Manifest Glaucoma Trial Group</collab>
            </person-group>
            <article-title>Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>120</volume>
            <issue>10</issue>
            <fpage>1268</fpage>
            <page-range>1268-79</page-range>
            <pub-id pub-id-type="pmid">12365904</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
